| Literature DB >> 32120954 |
Ran Xu1, Niel A Karrow1, Umesh K Shandilya1, Lv-Hui Sun2, Haruki Kitazawa3,4.
Abstract
Mycotoxins are toxic secondary fungal metabolites that commonly contaminate crops and food by-products and thus, animal feed. Ingestion of mycotoxins can lead to mycotoxicosis in both animals and humans, and at subclinical concentrations may affect animal production and adulterate feed and animal by-products. Mycotoxicity mechanisms of action (MOA) are largely unknown, and co-contamination, which is often the case, raises the likelihood of mycotoxin interactions. Mitigation strategies for reducing the risk of mycotoxicity are diverse and may not necessarily provide protection against all mycotoxins. These factors, as well as the species-specific risk of toxicity, collectively make an assessment of exposure, toxicity, and risk mitigation very challenging and costly; thus, in-vitro cell culture models provide a useful tool for their initial assessment. Since ingestion is the most common route of mycotoxin exposure, the intestinal epithelial barrier comprised of epithelial cells (IECs) and immune cells such as macrophages, represents ground zero where mycotoxins are absorbed, biotransformed, and elicit toxicity. This article aims to review different in-vitro IEC or co-culture models that can be used for assessing mycotoxin exposure, toxicity, and risk mitigation, and their suitability and limitations for the safety assessment of animal foods and food by-products.Entities:
Keywords: in-vitro cell culture; mycotoxins; toxicity assessment and mitigation
Mesh:
Substances:
Year: 2020 PMID: 32120954 PMCID: PMC7150844 DOI: 10.3390/toxins12030146
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Summary of effects of individual mycotoxins on intestinal epithelial cell (IEC) viability.
| Mycotoxin | IEC model | Exposure Duration | Tested Exposure Concentration | Cytotoxicity Assay | LC50/Effective Concentration (ECs) | References |
|---|---|---|---|---|---|---|
|
| Caco-2 (differentiated) | 24 h | 0, 1.39, 4.17, 12.5, 37.5 μM | LDH release | EC: 37.5 μM | [ |
| Caco-2 | 48 h | 0, 0.05, 0.1, 0.3, 0.5, 1, 3, 5, 10 μM | Luminescent Cell Viability Assay | LC50 =1.3 uM; EC: 0.5–10μM | [ | |
| Caco-2 | 24 h | 0, 0.25, 1, 2.5, 5, 10 μM | MTS Assay | LC50 = 10 μM | [ | |
| Neutral Red | LC50 = 3.7 μM | |||||
| 72 h | 0, 0.25, 1, 2.5, 5, 10 μM | MTS Assay | LC50 = 4.3 μM | |||
| Neutral Red | LC50 = 3.7 μM | |||||
| Caco-2 (differentiated) | 24 h | 0, 0.25, 1, 2.5, 5, 10 μM | MTS Assay | LC50 > 10 μM | [ | |
| Neutral Red | LC50 > 10 μM | |||||
| 72 h | 0, 0.25, 1, 2.5, 5, 10 μM | MTS Assay | LC50 > 10 μM | |||
| Neutral Red | LC50 > 10 μM | |||||
| Caco-2 | 72 h | 1–150 μM | Neutral Red | LC50 = 21.5 μM; EC: 10 μM | [ | |
| MTT Assay | LC50 = 25 μM; EC: 10 μM | |||||
| Caco-2 | 24 h | 0, 0.001, 0.01, 0.1, 1, 10, 25, 50, 100 μM | CCK-8 | LC50 = 21.94 μM | [ | |
| 48 h | LC50 = 9.39 μM | |||||
| 72 h | LC50 = 6.18 μM | |||||
| IPEC-1 | 24 h | 0, 0.34, 0.67, 1.7, 3.4, 6.7 10.2, 13.4 μM | MTT Assay | EC: 1.7, 3.4, 10.2, 13.4 μM | [ | |
| 48 h | EC: 0.34 μM; 1.7–13.4 μM | |||||
| 72 h | EC: 0.34 μM; 1.7- 13.4 μM | |||||
| IPEC-1 (in serum-free media) | 24 h | 0, 0.67, 6.7 μM | LDH release | NA | ||
| 48 h | EC: 6.7 μM | |||||
| 72 h | EC: 6.7 μM | |||||
| IPEC-1 (in complete media) | 24 h | 0, 0.67, 6.7 μM | Neutral Red | EC: 0.67, 6.7 μM | ||
| 48 h | EC: 6.7 μM | |||||
| 72 h | EC: 6.7 μM | |||||
| IPEC-1 (in serum-free media) | 24 h | 0, 0.67, 6.7 μM | Neutral Red | EC: 0.67, 6.7 μM | ||
| 48 h | EC: 6.7 μM | |||||
| 72 h | EC: 6.7 μM | |||||
| IPEC-J2 | 24 h | 0, 0.34, 0.67, 1.7, 3.4, 6.7 10.2, 13.4 μM | MTT Assay | EC: 0.34, 3.4, 6.7, 13.4 μM | [ | |
| 48 h | EC: 1.7–13.4 μM | |||||
| 72 h | EC: 1.7–13.4 μM | |||||
| 14 d | 0, 0.17, 0.34, 0.67, 1.02, 1.34, 1.7 μM | 0.67, 1.02, 1.34, 1.7 μM | ||||
| IPEC-J2 | 24 h | 0, 0.67, 6.7 μM | LDH release | NA | [ | |
| 48 h | EC: 6.7 μM | |||||
| 72 h | NA | |||||
| IPEC-J2 | 24 h | 0, 0.67, 6.7 μM | Neutral Red | EC: 0.67, 6.7 μM | [ | |
| 48 h | EC: 6.7 μM | |||||
| 72 h | EC: 6.7 μM | |||||
| IPEC-J2 (in serum-free media) | 24 h | 0, 0.67, 6.7 μM | Neutral Red | EC: 0.67, 6.7 μM | [ | |
| 48 h | EC: 6.7 μM | |||||
| 72 h | EC: 6.7 μM | |||||
| IPEC-J2 (basolateral) | 24 h | 0, 0.67, 1.7, 6.7, 13.4 μM | DAPI staining | NA | [ | |
| 48 h | EC: 6.7, 13.4 μM | |||||
| 72 h | EC: 6.7, 13.4 μM | |||||
| IPEC-J2 | 24 h | 0, 0.034, 0.085, 0.17, 0.34, 0.85, 1.7, 3.4, 17, 34 μM | Neutral Red | EC: 0.85–34 μM | [ | |
| IPEC-J2 | 72 h | 0, 3.4, 8.5, 17, 25.5, 34 μM | Annexin-V-FITC/ PI | EC: 8.5–34 μM | [ | |
| IPEC-J2 | 72 h | 0, 3.4, 17, 34, 51, 67 μM | Annexin-V-FITC/ PI | LC50 = 10.47 μM | [ | |
| IPEC-J2 (differentiated) | 72 h | 0, 3.4, 17, 34, 51, 67 μM | Annexin-V-FITC/ PI | LC50 = 46.9 μM | [ | |
| IPEC-J2 | 6 h | 0, 0.67, 6.7 μM | CCK-8 Assay | EC: 0.67, 6.7 μM | [ | |
| 12 h | ||||||
| 24 h | ||||||
| 48 h | ||||||
| 72 h | ||||||
| IPEC-J2 | 48 h | 0, 0.25, 0.5, 1, 2 μM | MTT Assay | LC50 = 1.83μM; EC:1–2 μM | [ | |
| IPEC-J2 | 24 h | 0, 0.43, 0.85, 1.7, 3.4, 6.7 μM | CCK-8 Assay | EC: 0.85–6.7 μM | [ | |
|
| Caco-2 | 72 h | 1–150 μM | Neutral Red | LC50 = 15 μM | [ |
| MTT Assay | LC50 = 25 μM | |||||
| Caco-2 | 24 h | 0, 0.001, 0.01, 0.1, 1, 10, 25, 50, 100 μM | CCK-8 | LC50 = 62.67 μM | [ | |
| 48 h | LC50 = 56.96 μM | |||||
| 72 h | LC50 = 34.36 μM | |||||
| IPEC-1 | 24 h | 0, 0.1, 1, 10, 100 μM | XTT Assay | EC: 100 μM | [ | |
| IPEC-1 | 24 h | 0, 0.1, 1, 10, 100 μM | XTT Assay | EC: 100 μM | [ | |
| 0, 0.1, 1, 10, 100 μM | Neutral Red | EC: 100 μM | ||||
| IPEC-J2 | 48 h | 0, 5, 10, 20, 40 μM | MTT Assay | EC: 10, 40 μM | [ | |
| IPEC-J2 | 48 h | 0, 15.5, 31, 62, 124, 248 μM | MTT Assay | LC50 = 62.1 μM; | [ | |
| IPEC-J2 | 72 h | 0, 19.9, 39.8, 44.73, 59.7, 79.6, 99.5 μM | Annexin-V-FITC/PI | EC: 44.73–99.5 μM | [ | |
| Caco-2 | 24 h | 0, 0.032, 0.16, 0.32, 1.6, 3.2 μM | MTT Assay | EC: 3.2 μM | [ | |
|
| 48 h | EC: 0.32—3.2 μM | ||||
| 72 h | EC: 1.6–3.2 μM | |||||
| Caco-2 (differentiated) | 24 h | 0, 0.032, 0.16, 0.32, 1.6, 3.2 μM | MTT Assay | EC: 1.6 μM | [ | |
| 48 h | EC: 1.6–3.2 μM | |||||
| 72 h | EC: 0.16–3.2 μM | |||||
| Caco-2 | 24 h | 0, 0.032, 0.16, 0.32, 1.6, 3.2 μM | LDH release | EC: 1.6–3.2 μM | [ | |
| 48 h | EC: 0.32–3.2 μM | |||||
| 72 h | EC: 0.32–3.2 μM | |||||
| Caco-2 (differentiated) | 24 h | 0, 0.032, 0.16, 0.32, 1.6, 3.2 μM | LDH release | EC: 3.2 μM | [ | |
| 48 h | EC: 0.032–3.2 μM | |||||
| 72 h | EC: 0.032–3.2 μM | |||||
| Caco-2 | 24 h | 0, 1,3, 10, 30, 100 μM | MTT Assay | LC50 = 5.39 μM | [ | |
| LDH release | LC50 = 10 μM | |||||
| Caco-2 | 24 h | 0–100 μM | Neutral Red | LC50 = 10 μM | [ | |
| 48 h | LC50 = 2 μM | |||||
| 72 h | LC50 = 0.75 μM | |||||
|
| Caco-2 | 48 h | 0, 399.6, 999 μM | Crystal Violet staining (CVS) | EC: 399.6, 999 μM | [ |
| HCT116 | 36 h | 0, 75, 150, 300 μM | Fluorescein diacetate (FDA) staining | LC50 = 300 μM; EC: 150- 300 μM | [ | |
|
| Caco-2 | 48 h | 0, 0.0078, 0.078, 0.78, 7.8, 78, 780 μM | MTS Assay | LC50 > 780 uM | [ |
| Caco-2 (differentiated) | ||||||
|
| Caco-2 | 24 h | 0, 1, 3, 10, 30, 100 μM | MTT Assay | LC50 = 21.25 μM; EC: 1–100 μM | [ |
| LDH release | LC50 = 16.85 μM; EC: 1–100 μM | |||||
| Caco-2 | 24 h | 1–200 μM | MTT Assay | LC50 = 145.36 μM | [ |
Summary of effects of selected mycotoxins on tight junction gene and protein expression.
| Mycotoxins | IEC model | Exposure Duration | Exposure Concentration | Effects of Selected Mycotoxins on Gene and Protein Expression of TJs | References | |
|---|---|---|---|---|---|---|
| Gene Expression | Protein Expression | |||||
| DON | Caco-2 | 24 h | 0, 1.39, 4.17, 12.5 μM | Increase in CLDN1, CLDN3, CLDN4, OCLN, ZO-1 | Decrease in CLDN1, CLDN3, CLDN4 | [ |
| Caco-2 | 24 h | 0, 0.17, 1.7, 17 μM | Increase in CLDN4, OCLN | Decrease in CLDN4 | [ | |
| Caco-2 | 48 h | 0, 5, 10, 20, 50, 100 μM | N/A | Decrease in CLDN4 | [ | |
| IPEC-1 | 48 h | 0, 5, 10, 20, 50 μM | N/A | Decrease CLDN3, CLDN4 | [ | |
| IPEC-1 | 48 h | 0.67, 6.7 μM | N/A | Decrease in ZO-1 | [ | |
| IPEC-J2 | 48 h | 0.67, 6.7 μM | N/A | Decrease in ZO-1 | [ | |
| IPEC-J2 | 12 h | 0, 4 μM | Decrease in CLDN3; increase CLDN4, OCLN, ZO-1 | Decrease CLDN3, CLDN4 | [ | |
| AFB1 | Caco-2 | 7 days | 0, 1,3, 10, 30 μM | Decrease in CLDN3, OCLN | N/A | [ |
| OTA | Caco-2 | 24 h | 0, 100 μM | N/A | Decrease in CLDN3 and CLDN4 | [ |
| Caco-2 | 24 h | 0, 100 μM | N/A | Decrease in CLDN3 and CLDN4 | [ | |
| Caco-2 | 7 days | 1, 3, 10, 30 μM | Decrease in CLDN3, CLDN4 and OCLN | N/A | [ | |